Company: Bristol-Myers Squibb ( BMY)

Drug/indication: Ipilimumab for melanoma

Estimated timing: Fourth quarter

Recent stock performance: At almost $26, trading close to its year high

Bristol was the star of the most recent ASCO cancer conference where the company presented positive results from a phase III study of ipilimumab in previously treated melanoma patients. Bristol plans to seek FDA approval for ipilimumab based on these data despite some lingering questions about the strength of the results.

Bristol can put all the questions about ipilimumab to rest with boffo results from this next phase III study in 500 first-line, or newly treated melanoma patients. The study compares ipilimumab plus the chemotherapy DTIC against DTIC plus a placebo, with overall survival as the primary endpoint.

If you liked this article you might like

After Soaring to $150, Can Incyte Stir Up More Upside?

Biotech Buoyed by Deal Talk

The Next Target in Biotech Land

The Next Target in Biotech Land

Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)